Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 271 participants.
Also called NCT05476354
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 271 participants
- Sponsor
- Registry
-
NCT05476354
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05476354. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-05 (actual); primary completion 2023-04-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
- Condition
- Essential Hypertension
- Intervention (Drug)
- Irbesartan/Amlodipine low
- Intervention (Drug)
- Irbesartan/Amlodipine high
- Intervention (Drug)
- Irbesartan
- Lead sponsor
- Handok Inc.
Record details
- Record id
cardio:ct-nct05476354- Content hash
c4b2d2e0eb62f273cd3d8b8b8f9b567f5b61b85e25165d18b3f3111a61868ed5